2024-01-29 13:47:30 ET
Summary
- Today, we take a look at Legend Biotech Corporation, a commercial-stage biopharmaceutical company focused on developing cell therapies for oncology and other indications.
- The company has one approved product on the market, LCAR-B38M, for the treatment of multiple myeloma. This product is a potential blockbuster and also known as Carvykti.
- Most analyst firms are positive about Legend Biotech's prospects, with price targets ranging from $85 to $100 per share.
- The company also inked a new licensing deal with Novartis in November.
- An investment analysis of Legend Biotech Corporation follows in the paragraphs below.
Legends are best left as legends and attempts to make them real are rarely successful "? Michael Moorcock.
Read the full article on Seeking Alpha
For further details see:
Legend Biotech: Solid Traction With Carvykti Rollout